Skip to main content
 

Featured Items |view more

Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer News

Immunotherapy – Targeted Drug Combination Improves Survival in Advanced Kidney Cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent have longer survival than patients treated with the standard targeted drug.

Institute Research Shines at Society of Gynecologic Oncology Annual Meeting News

Institute Research Shines at Society of Gynecologic Oncology Annual Meeting

Researchers in the Division of Gynecologic Oncology reported results from an array of clinical trials, gave an overview of trials currently under way, and presented promising findings from the lab.

High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival News

High Concentrations of Immune Cells Within Tumors Associated with Longer Patient Survival

ImmunoPROFILE: A prospective implementation of clinically validated, quantitative immune cell profiling test identifies tumor-infiltrating CD8+ and PD-1+ cell densities as prognostic biomarkers across a 2,023 patient pan-cancer cohort ...

Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma News

Clinical Trial Shows That Adding Bevacizumab to Targeted Drug and Chemotherapy Produces Striking Activity Against HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

Long-term results and ctDNA correlatives for CAPOX BETR: A multi-center phase II trial of capecitabine, oxaliplatin, bevacizumab and trastuzumab for previously untreated HER2 positive metastatic gastroesophageal adenocarcinoma

Personal Organoids Could Help Individualize Cancer Treatment News

Personal Organoids Could Help Individualize Cancer Treatment

Individualizing treatment using patient derived organoids, BH3 profiling and microfluidics: A proof of concept in a patient with low-grade serous ovarian carcinoma